ASKA Pharmaceutical Holdings (4886) · InitiativeFirst statedLatest Financial results presentation (2026-08-04): "Restated"
Clinical Development of LPRI-CF113 for Dysmenorrhea
First written in FY2025. 1 of 2 entries say "Restated". Latest entry: 2026-08-04.
2entries
2years
1from disclosures
How it moved
Same theme, other companies
Clinical Development of LPRI-CF113 for DysmenorrheaA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-08-04RestatedFinancial results presentation
「LPRI-CF113 (drospirenone) Dysmenorrhea Ph I/II ongoing」
The company reconfirmed that Phase I/II trials of LPRI-CF113 for dysmenorrhea are ongoing. - FY2025First statedAnnual report
「また、月経困難症を適応症として導入したLPRI-CF113（ドロスピレノン）は2025年３月からPhaseⅠ/Ⅱ試験を開始しております。」
導入したドロスピレノン製剤LPRI-CF113について、月経困難症を適応症とするPhaseⅠ/Ⅱ試験を2025年3月から開始した。